Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World's First Fully Recoverable Self-Expanding Dry-Valve TAVR System

Venus Medtech (02500.HK) said its PREVAILS study is now fully enrolled, a key step toward submitting applications simultaneously in China and Europe for its next-generation TAVR system. The update supports the company’s development and regulatory timeline, which is likely to be viewed positively but may have limited near-term financial impact given no efficacy/safety or commercial milestones were disclosed.

Analysis

Venus Medtech (02500.HK) said its PREVAILS study is now fully enrolled, a key step toward submitting applications simultaneously in China and Europe for its next-generation TAVR system. The update supports the company’s development and regulatory timeline, which is likely to be viewed positively but may have limited near-term financial impact given no efficacy/safety or commercial milestones were disclosed.